Filtered By:
Condition: Heart Attack
Countries: Sweden Health

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 118 results found since Jan 2013.

Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
ConclusionsThis large, multinational study found no higher risk of MACE, AMI, stroke, CV mortality or all-cause mortality among users of mirabegron relative to users of antimuscarinics.
Source: Drug Safety - August 1, 2021 Category: Drugs & Pharmacology Source Type: research

Cardiovascular Event Rates After Myocardial Infarction or Ischaemic Stroke in Patients with Additional Risk Factors: A Retrospective Population-Based Cohort Study
ConclusionDespite previous use of moderate- or high-intensity statins, patients with a history of MI or IS, and additional risk factors remain at very high cardiovascular risk.
Source: Advances in Therapy - July 26, 2021 Category: Drugs & Pharmacology Source Type: research

Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
ConclusionsThis large, multinational study found no higher risk of MACE, AMI, stroke, CV mortality or all-cause mortality among users of mirabegron relative to users of antimuscarinics.
Source: Drug Safety - July 8, 2021 Category: Drugs & Pharmacology Source Type: research

Country of birth and mortality risk in hypertension with and without diabetes: the Swedish primary care cardiovascular database
Conclusion: In Sweden, hypertensive immigrants (with the exception for Finnish-born) with and without diabetes have a mortality advantage, as compared to Swedish-born.
Source: Journal of Hypertension - May 14, 2021 Category: Cardiology Tags: ORIGINAL PAPERS: Blood pressure epidemiology Source Type: research

Vascular ultrasound for cardiovascular risk stratification in asymptomatic patients with type-2 diabetes
CONCLUSION: Duplex ultrasonography to screen for atherosclerotic plaques improve the estimation of cardiovascular prognosis on top of clinical data and could be routinely used to improve cardiovascular risk stratification.PMID:33896756 | DOI:10.1016/j.pcd.2021.04.006
Source: Primary Care - April 26, 2021 Category: Primary Care Authors: Angeladine Kenne Malaha Julien Magne Lucile Jarlan Katia Mansour Melissa Ait-Ouatet Sophie Galinat Marie-Pierre Teissier Philippe Lacroix Ileana Desormais Victor Aboyans Source Type: research

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Plasma Protein Profile of Carotid Artery Atherosclerosis and Atherosclerotic Outcomes: Meta-Analyses and Mendelian Randomization Analyses
CONCLUSIONS: The present meta-analysis discovered several proteins related to carotid atherosclerosis that partly differed in their association with IMT-CCA, plaque, and incident atherosclerotic disease. Mendelian randomization analysis for the top finding, MMP-12, suggests that the increased levels of MMP-12 could be a consequence of atherosclerotic burden rather than the opposite chain of events.PMID:33657885 | DOI:10.1161/ATVBAHA.120.315597
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 4, 2021 Category: Cardiology Authors: Lars Lind Bruna Gigante Yan Born é Tobias Feldreich Jerzy Leppert P är Hedberg Carl Johan Östgren Fredrik H Nystr öm Johan Sundstr öm Johan Ärnlöv Damiano Baldassarre Elena Tremoli Fabrizio Veglia Anders Hamsten Christopher J O'Donnell Nora Frances Source Type: research

Use of sodium –glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry
ConclusionIn a contemporary HF cohort with T2DM, SGLT2i use increased over time, was more common with specialist care, younger age, ischaemic heart disease, and preserved renal function, and was associated with lower mortality and morbidity.
Source: European Journal of Heart Failure - March 3, 2021 Category: Cardiology Authors: Peter M. Becher, Benedikt Schrage, Giulia Ferrannini, Lina Benson, Javed Butler, Juan Jesus Carrero, Francesco Cosentino, Ulf Dahlstr öm, Linda Mellbin, Giuseppe M.C. Rosano, Gianfranco Sinagra, Davide Stolfo, Lars H. Lund, Gianluigi Savares Tags: Research Article Source Type: research